The intratumoral administration of plasmid IL-12 provides a critical bridge between innate and adaptive immunity to meet the above requirements by recruiting and activating natural killer (NK), NKT, and CD4+ and/or CD8+ T cells into the tumor microenvironment with less toxicity. This evidence concerns the gene CD8A and neoplasm.